Literature DB >> 2984982

Duration of effect of interferon aerosol prophylaxis of vesicular stomatitis virus infection in mice.

P R Wyde, C S Sun, S Z Wilson, V Knight.   

Abstract

Mice were exposed for 8 h to continuous small-particle aerosols containing natural mouse alpha interferon (estimated dosage 100 U per mouse) or one of two concentrations of hybrid recombinant alpha interferon A/D bgl (estimated dosages of 100 and 10,000 U per mouse, respectively). On days 1, 3, 5, 7, and 9 after exposure to these interferons, three mice from each group were inoculated intranasally with 100 PFU of vesicular stomatitis virus. Control mice were exposed to aerosols of saline or inoculated intraperitoneally with either natural mouse alpha interferon (350 U) or one of two doses of hybrid recombinant alpha interferon A/D bgl (350 or 35,000 U) and challenged similarly. Of mice injected intraperitoneally, only those given 35,000 U of hybrid recombinant alpha interferon A/D bgl 24 h before virus challenge were protected from pulmonary infection, compared with the saline-treated control mice. Of mice given 100 U of either interferon by small-particle aerosol, only those exposed 24 h before inoculation of vesicular stomatitis virus had reduced pulmonary titers of the virus. However, of mice given ca. 10,000 U of hybrid recombinant alpha interferon A/D bgl by small-particle aerosol, all groups except those exposed 9 days before virus inoculation had significantly reduced lung virus titers.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984982      PMCID: PMC176205          DOI: 10.1128/AAC.27.1.60

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  INTERFERON.

Authors:  A ISAACS
Journal:  Adv Virus Res       Date:  1963       Impact factor: 9.937

2.  Fate of intravenously administered interferon and the distribution of interferon during virus infections in mice.

Authors:  T P Subrahmanyan; C A Mims
Journal:  Br J Exp Pathol       Date:  1966-04

Review 3.  The human interferons--from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond.

Authors:  S Pestka
Journal:  Arch Biochem Biophys       Date:  1983-02-15       Impact factor: 4.013

4.  Specific molecular activities of recombinant and hybrid leukocyte interferons.

Authors:  E Rehberg; B Kelder; E G Hoal; S Pestka
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

5.  The influence of route of administration of interferon on its therapeutic effect.

Authors:  Z Blach-Olszewska; R Mazur; Z Skurska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1972       Impact factor: 4.291

6.  Persistence and spread of influenza virus (A2-Hong Kong) in normal and poly I.C. treated baboons (Papio cynocephalus).

Authors:  R L Heberling; S S Kalter
Journal:  Proc Soc Exp Biol Med       Date:  1970-12

7.  Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats.

Authors:  C S Sun; P R Wyde; S Z Wilson; V Knight
Journal:  J Interferon Res       Date:  1984

8.  Interferon aerosol suppression of vesicular stomatitis virus replication in the lungs of infected mice.

Authors:  P R Wyde; S Z Wilson; C S Sun; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

9.  Pulmonary deposition and clearance of aerosolized interferon.

Authors:  P R Wyde; S Z Wilson; M J Kramer; C S Sun; V Knight
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

10.  The results of controlled observations on the prophylaxis of influenza with interferon.

Authors:  V D Solov'ev
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  1 in total

1.  Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice.

Authors:  K Sudo; W Watanabe; K Konno; R Sato; T Kajiyashiki; S Shigeta; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.